Podcast
Bench to Boardroom
Hosted by Pharmaconcepts · ENGLISH
Bench to Boardroom is a highly curated podcast for life sciences leaders who value signal over noise. Each concise episode distills the most relevant ideas, trends, and strategic insights shaping biotech, pharma, medtech, and healthcare today—always practical, always actionable. Select episodes feature distinguished guests sharing real-world perspectives from the front lines of innovation and leadership.
5episodes
Episodes
Newest firstAll episodes
The New Economics of Launch
3d ago00:10:33Tap to summarizeIn this episode of Bench to Boardroom, we examine why maximizing value across a life sciences portfolio increasingly requires an asset-specific, geography-agnostic approach rather than relying on the traditional “U.S. first, Europe second, rest of world later” launch model. Through examples in oncology/hematology, cell and gene therapy, and immunology, the discussion explores how launch sequencing, emerging regulatory pathways, evidence generation, market access strategy, and international pricing dynamics can materially influence net present value (NPV), time to patient access, and long-term commercial success. The episode argues that the most valuable portfolios of the future will be built not by following convention, but by strategically matching each asset with the launch sequence that optimizes both enterprise value and patient impact.
Transcribe →The Technology Allocation Trap
2w ago00:12:14Tap to summarizeIn this episode of Bench to Boardroom, we explore why not all technology investments in life sciences are created equal — and why following the hype around AI and digital transformation may generate far weaker returns than many executives expect. The discussion examines where emerging technologies can create meaningful strategic advantage across clinical development, commercialization, market access, launch sequencing, regulatory intelligence, manufacturing, and supply chain operations, while also highlighting where excessive or poorly targeted tech investment may lead to diminishing returns. Ultimately, the episode argues that the leaders who win with technology are not those investing the most, but those investing most intelligently — aligning technology with the realities of science, operations, and commercial execution.
Transcribe →The New Launch Playbook
May 1100:12:23Tap to summarizeLaunching innovative medicines can no longer follow conventional precedent. The old formula -- U.S. first, Europe second, rest of world later -- is increasingly misaligned with the realities of today’s health policy, pricing, and market access environment. And for some assets, following the traditional launch sequence may actually destroy long-term value. Not because the science is flawed. But because the strategy is.
Transcribe →Portfolio Strategy
Apr 2700:11:51Tap to summarizeThe term Portfolio Strategy gets used constantly in life sciences. Board decks use it. Investors use it. Management teams use it. Consultants use it. But too often, portfolio strategy is treated as a static spreadsheet exercise -- ranking assets, cutting budgets, and reallocating headcount. In this episode, we discuss why (and how) real portfolio strategy is far more consequential than that.
Transcribe →Inaugural Episode
Apr 2400:03:50Tap to summarizeShort trailer introducing the Bench to Boardroom podcast
Transcribe →